share_log

啓明醫療-B：(1) 復牌進展季度更新；及(2) 繼續暫停買賣

VENUS MEDTECH-B: (1) QUARTERLY UPDATE ON RESUMPTION PROGRESS; AND(2) CONTINUED SUSPENSION OF TRADING

HKEX ·  May 23, 2024 22:46

Summary by Futu AI

啟明醫療-B（股份代號：2500）於2024年5月23日發布公告，更新了公司復牌進展及繼續暫停買賣的情況。公告提及了一系列過去的事件，包括未經授權交易的法證調查結果、內部控制檢討的完成，以及管理層變動。公司業務營運正常，並無因未經授權交易而受重大影響。公司已針對未經授權交易進行法證調查，並已償還或解除相關款項。此外，公司已完成內部控制檢討，並認為已建立足夠的內部控制系統。公司高層人事變動包括訾先生、曾先生及馬先生的辭職，以及王飛先生的任命為首席財務官。公司正尋找合適人選填補獨立非執行董事及董事委員會的空缺，以符合上市規則及復牌指引的要求。
啟明醫療-B（股份代號：2500）於2024年5月23日發布公告，更新了公司復牌進展及繼續暫停買賣的情況。公告提及了一系列過去的事件，包括未經授權交易的法證調查結果、內部控制檢討的完成，以及管理層變動。公司業務營運正常，並無因未經授權交易而受重大影響。公司已針對未經授權交易進行法證調查，並已償還或解除相關款項。此外，公司已完成內部控制檢討，並認為已建立足夠的內部控制系統。公司高層人事變動包括訾先生、曾先生及馬先生的辭職，以及王飛先生的任命為首席財務官。公司正尋找合適人選填補獨立非執行董事及董事委員會的空缺，以符合上市規則及復牌指引的要求。
Kai Ming Medical -B (stock code: 2500) issued a notice on 23 May 2024, updating the company's re-licensing progress and continuing to suspend trading. The announcement mentions a series of past events, including the results of forensic investigations into unauthorized transactions, the completion of internal control reviews, and management changes. The Company's business is operating normally and is not significantly affected by unauthorized transactions. THE COMPANY HAS CONDUCTED A FORENSIC INVESTIGATION INTO THE UNAUTHORIZED TRANSACTION AND HAS REPAID OR CANCELED THE RELEVANT FUNDS. In addition, the company has completed an internal control review and considers that an adequate internal control system has been established. Senior personnel changes at the company include the resignations of Mr. Tsang, Mr. Tsang and Mr. Ma, and the appointment of Mr. Wang Fei as Chief Financial Officer. The Company is seeking the right person to fill vacancies for independent non-executive directors and board committees to meet the requirements of the Listing Rules and the Replication Guidelines.
Kai Ming Medical -B (stock code: 2500) issued a notice on 23 May 2024, updating the company's re-licensing progress and continuing to suspend trading. The announcement mentions a series of past events, including the results of forensic investigations into unauthorized transactions, the completion of internal control reviews, and management changes. The Company's business is operating normally and is not significantly affected by unauthorized transactions. THE COMPANY HAS CONDUCTED A FORENSIC INVESTIGATION INTO THE UNAUTHORIZED TRANSACTION AND HAS REPAID OR CANCELED THE RELEVANT FUNDS. In addition, the company has completed an internal control review and considers that an adequate internal control system has been established. Senior personnel changes at the company include the resignations of Mr. Tsang, Mr. Tsang and Mr. Ma, and the appointment of Mr. Wang Fei as Chief Financial Officer. The Company is seeking the right person to fill vacancies for independent non-executive directors and board committees to meet the requirements of the Listing Rules and the Replication Guidelines.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated